Table 1.
Differentially expressed genes of enriched pathways. HA treatment enriched only pathways relating to TGF-β signalling and ECM–receptor interactions. Fold changes represent the gene expression of neotissue at 4 days treated with HA (1 mg ml–1, 1.6 × 106 Da HA) relative to control values.
| gene | fold change | regulation |
|---|---|---|
| TGF-β pathway targets | ||
| activin | 6.82 | up |
| inhibitor of DNA binding 1 | 8.57 | down |
| inhibitor of DNA binding 2 | 4.67 | up |
| c-Myc transcription factor | 5.34 | up |
| E2F4 transcription factor | 4.78 | up |
| protein phosphatase | 3.47 | up |
| thrombospondin 1a | 4.92 | up |
| thrombospondin 2a | 8.22 | up |
| thrombospondin 3a | 4.26 | up |
| thrombospondin 4a | 6.82 | up |
| ECM–receptor pathway targets | ||
| chondroadherin | 13.42 | up |
| collagen, type I, α1 | 4.92 | down |
| collagen, type II, α1 | 4.47 | up |
| collagen, type III, α1 | 3.42 | up |
| collagen, type XI, α2 | 5.01 | up |
| integrin-α7 | 4.07 | up |
| syndecan 4 | 5.52 | up |
aTargets that were differentially expressed in both the TGF-β signalling and ECM–receptor interactions pathways.